Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs 1,319

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,319 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 3 of 28

  1. 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

    Telix Innovations

    Soft Tissue Sarcoma

    phase 1 small molecule active

    1 trial

  2. 89Zr-Girentuximab

    Telix Innovations

    Urothelial Carcinoma

    phase 1 small molecule completed

    1 trial

  3. 89Zr-Girentuximab

    Telix Innovations

    Clear Cell Renal Carcinoma

    phase 1 other completed

    1 trial

  4. 89Zr-girentuximab

    Telix Innovations

    Carcinoma, Renal Cell

    phase 1 other completed

    1 trial

  5. 89Zr˗DFO˗REGN5054

    Regeneron UK Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  6. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Refractory Cancer

    phase 1 small molecule terminated

    1 trial

  7. 90189892AML1001

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  8. 90301900HNC1001

    Janssen-Cilag International N.V.

    Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

    phase 1 other active

    1 trial

  9. 950P1V02

    Toray International U.K. Limited

    Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor

    phase 1 other active

    1 trial

  10. 99mTc-QULIC-5-P1

    The First People's Hospital of Lianyungang

    Prostate Cancer Stage

    phase 1 small molecule active

    1 trial

  11. A Multicentre for High-Risk, Surgically Resectabl…

    Fondazione Telethon ETS

    High-Risk, Surgically Resectable Melanoma

    phase 1 other active

    1 trial

  12. A Phase 1 Open-label Study to Assess the Safety for Solid Tumors

    Pasithea Therapeutics

    Solid Tumors

    phase 1 other active

    1 trial

  13. A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations

    Hutchmed Europe B.V.

    - Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation

    phase 1 other active

    1 trial

  14. A Phase 1 Study of JNJ-79032421 Targeting Mes... for Advanced Stage Solid Tumors

    Janssen-Cilag International N.V.

    Advanced Stage Solid Tumors

    phase 1 other active

    1 trial

  15. A Phase 1 Study of JNJ-87890387 for Advanced Solid Tumors

    Janssen-Cilag International N.V.

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  16. A Phase 1 Study on the effects of LY3410738 (...

    Eli Lilly Co.

    Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.

    phase 1 other active

    1 trial

  17. A Phase 1 for Advanced Non-Small Cell Lung Cancer

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  18. A Phase 1 for Relapsed/refractory B-cell Non…

    Janssen-Cilag International N.V.

    Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    phase 1 other active

    1 trial

  19. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  20. A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors

    Janssen-Cilag International N.V.

    Locally advanced, metastatic NSCLC, CRC, or HNSCC that has recurred or progressed after prior stand of care therapy

    phase 1 other active

    1 trial

  21. A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors

    Wuhan Createrna Science and Technology Co., Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  22. A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  23. A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

    Enliven Therapeutics

    Chronic myeloid leukemia

    phase 1 other active

    1 trial

  24. A Phase 1a/1b for Advanced, metastatic or unresec…

    BEONE MEDICINES AUS PTY LTD

    Advanced, metastatic or unresectable solid tumors

    phase 1 other active

    1 trial

  25. A Phase 1a/b Study Investigating the Safety for Advanced, or metastatic solid t…

    BEONE MEDICINES AUS PTY LTD

    Advanced, or metastatic solid tumors with methylthioadenosine phosphorylase (MTAP) homozygous deletion and/or lost MTAP protein expression

    phase 1 other active

    1 trial

  26. A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer

    Amgen

    Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer

    phase 1 other active

    1 trial

  27. A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced solid tumors

    phase 1 other active

    1 trial

  28. A Phase I for Relapse/ refractory acute Leukemia

    The George Institute

    Relapse/ refractory acute Leukemia

    phase 1 other active

    1 trial

  29. A Study of GEN1106 in Participants with Solid Tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  30. A Study of LY3200882 in Participants With Solid Tumors.

    Eli Lilly Co.

    Metastatic cancer, Solid Tumor

    phase 1 other active

    1 trial

  31. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    Eli Lilly Co.

    Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor

    phase 1 other active

    1 trial

  32. A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.

    Eli Lilly Co.

    Cancer

    phase 1 other active

    1 trial

  33. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    Eli Lilly Co.

    Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis

    phase 1 other active

    1 trial

  34. A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors

    Pfizer Australia Pty Ltd

    Melanoma (or) malignant melanoma Non-small cell lung cancer Head and neck squamous cell carcinoma Esophageal cancer

    phase 1 other active

    1 trial

  35. A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

    Alnylam Netherlands B.V.

    Advanced or Metastatic Hepatocellular Carcinoma

    phase 1 other active

    1 trial

  36. A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors

    AstraZeneca AB

    Advanced solid tumours

    phase 1 other active

    1 trial

  37. A Study to Learn If the Study Medicine Called...

    Pfizer Australia Pty Ltd

    ER+/HER2 positive breast cancer

    phase 1 other active

    1 trial

  38. A clinical study of MK-0472 in people with solid tumors (MK-0472-001)

    Merck Sharp and Dohme

    Malignant Neoplasm - Solid Tumors

    phase 1 other active

    1 trial

  39. A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

    Novartis Pharmaceuticals

    Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)

    phase 1 other active

    1 trial

  40. A study of ASP3082 in adults with advanced solid tumors

    Astellas Pharma GmbH

    Solid Tumor

    phase 1 other active

    1 trial

  41. A study to find a suitable dose of ASP5834 in adults with solid tumors

    Astellas Pharma GmbH

    Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification

    phase 1 other active

    1 trial

  42. A study to learn how safe the study drug BAY... for Advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  43. A-CAR028

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 1 mab active

    1 trial

  44. AB308

    Arcus Biosciences

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  45. AB598

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  46. AB680

    Arcus Biosciences

    Advanced Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  47. AB801

    Arcus Biosciences

    Cancer

    phase 1 small molecule completed

    1 trial

  48. AB801

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,319 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.